Other genetic studies have associated a polymorphism located in the LRP2 promoter with AD risk, regardless of the ApoE genotype [56], as well as some LRP2 germ-line polymorphisms with increased risk of prostate cancer recurrence [57]. This evidence concerns the gene LRP2 and prostate carcinoma.